Finance Watch: Biopharma IPO Queue Grows As Market Conditions Improve

Verrica, IGM Reveal Restructuring Plans

Public Company Edition: Septerna, Apimeds, CAMP4 and Upstream filed paperwork with the SEC aiming to take advantage of renewed investor interest in IPOs. Also, Biohaven closed a $287.5m offering and Grifols subsidiary GigaGen obtained up to $135m from BARDA.

Finance Watch Public Company — • Source: Alamy

The market for initial public offerings in the US heated up in September with five biopharmaceutical companies launching IPOs, the second busiest month for first-time offerings in 2024 after there were six in February. The September surge brought the year’s total to 20 biopharma IPOs, and it seemed to encourage more companies to enter the queue, since four firms filed paperwork with the US Securities and Exchange Commission (SEC) between 18 September and 2 October in support of future offerings.

Coincidentally, 18 September was a big day for biopharma and other industries in the US as the US Federal Reserve Board’s Federal Open Market Committee (FOMC) decided to lower interest...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Angelini Advances Brain Health Ambitions With GRIN Pact

27 May 2025

• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

27 May 2025

• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.

Finance Watch: Public Company Fundraising Sank Across The Board In Q1

23 May 2025

• By Mandy Jackson

Public Company Edition: Biomedtracker’s first quarter 2025 financing report shows follow-on offerings, IPOs and PIPEs fell sharply from Q1 of 2024. In recent transactions, Teva sold $2.3bn worth of notes, Regenxbio executed a royalty deal for up to $250m and Aura’s FOPO grossed $75m.

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

22 May 2025

• By Mandy Jackson

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.